OR-005

OR-005 is a preclinical therapeutic candidate under development by OccamzRazor for the treatment of Parkinson's disease. The drug was identified using the company's proprietary AI-driven discovery platform, which integrates multi-omic data and clinical information to map molecular pathways of neurodegeneration. OR-005 is specifically designed to target the "Lifestyle" patient subgroup, a classification defined by OccamzRazor's patient stratification model that categorizes Parkinson's patients based on their unique disease-driving pathways. As of 2024, the specific molecular target, modality, and mechanism of action for OR-005 have not been publicly disclosed by the sponsor.